secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENSAR, Inc. (LNSR)
CIK:        0001320350
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001564590-22-007866
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts LENSAR's 510(k) for ALLY Adaptive Cataract Treatment System for substantive review
--------------------------------------------------------------------------------

- 510(k) submission for next-gen ALLY system accepted for substantive review by FDA.
- Company plans two-step release: additional 510(k) for phacoemulsification features later in 2022.
- Expects ALLY launch in H2 2022 if marketing clearance is granted.
- Conference call on March 3, 2022 to discuss Q4 and full year 2021 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022007866/0001564590-22-007866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022007866/lnsr-8k_20220301.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-007866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer